

Integral BioSystems to Exhibit at the ARVO Annual Meeting in Salt Lake City, Utah from May 4 - May 7, 2025

Boston area drug delivery firm Integral BioSystems LLC will display in Booth 1321 May 4-7 at the Salt Palace Convention Center, Salt Lake City, Utah.



Integral BioSystems

Integral BioSystems Logo

BEDFORD, MA, UNITED STATES, March 13, 2025 /EINPresswire.com/ -- [Integral BioSystems LLC](#), Boston area drug

delivery CRO specializing in ophthalmological pharmaceutical formulation development, will be in the spotlight as a participating exhibitor (Booth 1321) during the ARVO 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology to be held at the Salt Palace Convention Center, Salt Lake City, Utah.



Integral BioSystems drug delivery technologies will maximize the effectiveness of your active ingredient"

Dr. Shikha Barman

With over 30 years of experience in all phases of tissue targeted, sustained release pharmaceutical formulation development, the firm's founder, President and CEO Dr. Shikha P. Barman, and company R&D Head Kevin Ward, will be on hand to discuss the specific requirements of interested attendees.

ABOUT INTEGRAL BIOSYSTEMS

Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems. For those seeking to develop a formulation for a new drug substance, a 505b2 product or a generic drug product, Dr. Barman will be available to answer questions about the suitability of Integral's recently patented drug delivery platform technologies NanoM-Wafer™ and OcuHeal™ for your particular application.

The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes. The company offers rapid proof-of-concept feasibility formulations or development toward IND submission, including cGLP services.

ABOUT THE SYMPOSIUM

The ARVO 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology will cover pioneering and current R&D on pharmacological therapies-in-development to treat ocular disorders, in both anterior and posterior segments of the eye. This gathering of scientists, medical personnel, and representatives from related businesses combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services. It is anticipated that approximately 11,000 people will participate in this meeting.

Dave Karasic
Integral BioSystems, LLC
+1 617-820-8483
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/793541661>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.